The historical rank and industry rank for WuXi Biologics (Cayman)'s Price-to-Free-Cash-Flow or its related term are showing as below:
FRA:1FW2'
s Price-to-Free-Cash-Flow Range Over the Past 10 Years
Min: 0 Med: 0 Max: 181.9
Current: 48.32
During the past 10 years, WuXi Biologics (Cayman)'s highest Price-to-Free-Cash-Flow Ratio was 181.90. The lowest was 0.00. And the median was 0.00.
FRA:1FW2's Price-to-Free-Cash-Flow is ranked worse than 62.15% of 214
companies
in the Biotechnology industry
Industry Median: 30.52
vs FRA:1FW2: 48.32
During the past 3 years, the average Free Cash Flow per Share Growth Rate was 47.20% per year.
During the past 5 years, the average Free Cash Flow per Share Growth Rate was -6.90% per year.
During the past 10 years, WuXi Biologics (Cayman)'s highest 3-Year average Free Cash Flow per Share Growth Rate was 47.20% per year. The lowest was -119.10% per year. And the median was -63.55% per year.
WuXi Biologics (Cayman) Price-to-Free-Cash-Flow Historical Data
The historical data trend for WuXi Biologics (Cayman)'s Price-to-Free-Cash-Flow can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of WuXi Biologics (Cayman)'s Price-to-Free-Cash-Flow
For the Biotechnology subindustry, WuXi Biologics (Cayman)'s Price-to-Free-Cash-Flow, along with its competitors' market caps and Price-to-Free-Cash-Flow data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
WuXi Biologics (Cayman)'s Price-to-Free-Cash-Flow Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, WuXi Biologics (Cayman)'s Price-to-Free-Cash-Flow distribution charts can be found below:
* The bar in red indicates where WuXi Biologics (Cayman)'s Price-to-Free-Cash-Flow falls into.
WuXi Biologics (Cayman)'s Share Price of today is €1.6402.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. WuXi Biologics (Cayman)'s Free Cash Flow per Share for the trailing twelve months (TTM) ended in Jun. 2023 was €0.03.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
Free Cash Flow is considered more important than earnings by value investors. The reason is because, in principle, only the net cash that can be taken from the business belongs to shareholders. This Free Cash Flow can be used to grow the business, reduce debt or return to shareholders in dividends or share buybacks.
In a DCF Calculation Free Cash Flow is used to determine the intrinsic value of companies.
Be Aware
In real business, Free Cash Flow can be affected by the change in accounts receivable, accounts payable, management's decision on expansion, etc. Therefore, investors should look at the Free Cash Flow over the longer term. Long-term average of Free Cash Flow is a more reliable indicator for real free cash flow.
WuXi Biologics (Cayman) Price-to-Free-Cash-Flow Related Terms
Thank you for viewing the detailed overview of WuXi Biologics (Cayman)'s Price-to-Free-Cash-Flow provided by GuruFocus.com. Please click on the following links to see related term pages.
WuXi Biologics (Cayman) (FRA:1FW2) Business Description
WuXi Biologics is one of the largest global biologics CRDMOs. WuXi Biologics, incorporated in 2014 following the reorganization of WuXi PharmaTech, later known as WuXi AppTec, now has global revenue of CNY 15 billion. North American represented 55.6% of total revenue in 2022. It adopts the follow and win the molecule strategy by providing end-to-end services, from drug discovery to commercial manufacturing. It also adopts a global dual-sourcing strategy by providing drug products and large-scale drug substance manufacturing.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
FRA:1FW2 has been successfully added to your 